Holen Sie sich die Stockscreener-App
24.54
1.88%
-0.47
Handel nachbörslich:
24.55
0.01
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - Yahoo Finance
Pfizer stock stabilizes as oncology and vaccine pipeline shapes outlook - AD HOC NEWS
Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win - Law360
Pfizer’s ex-comms leader joins Vantage Data Centers - Medical Marketing and Media
Pfizer stock trades steadily as recent earnings and pipeline shape investor sentiment - AD HOC NEWS
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push - simplywall.st
Samsung, Celltrion Join Nectin-4 ADC Race, Challenging Pfizer's Padcev Dominance - finance.biggo.com
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer - The Globe and Mail
Pfizer building incident pits banner project with a conversion pitfall - The Real Deal
Pfizer (NYSE:PFE) Leads Healthcare Focus on Balance-Sheet Strength - Kalkine Media
Pfizer stock trades steady as Pfizer India posts stronger FY 2024 earnings - Ad-hoc-news.de
Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access - Bloomberg Law News
Pfizer stock steadies as investors weigh pipeline progress and recent earnings - Ad-hoc-news.de
Pfizer Prevnar 20 by Pfizer Inc.broader adult protection in one syringe - Ad-hoc-news.de
Pfizer Inc (0Q1N) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
What Makes Pfizer (NYSE:PFE) Stand Out in the S&P 500? - Kalkine Media
Pfizer (PFE) Secures Priority Review for Talzenna in Prostate Ca - GuruFocus
Pfizer’s prostate cancer drug combination gets US FDA priority review - 1470 & 100.3 WMBD
Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use - Investing.com
Pfizer trial: TALZENNA combo cut progression-or-death risk 52% - Stock Titan
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck - HIT Consultant
Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology - simplywall.st
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Pfizer (NYSE:PFE) Oncology Growth Faces A Major Valuation Test - Kalkine Media
Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones - Ad-hoc-news.de
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine - Fierce Pharma
Prevnar 20 by Pfizerbroader pneumococcal protection for adults - Ad-hoc-news.de
PFE Stock Quote Price and Forecast - CNN
Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build - simplywall.st
PR News | Pfizer Pro Harnaga Takes Vantage Data PostTue., Jul. 21, 2026 - O'Dwyer's PR
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - Yahoo Finance
8 Lessons I’ve Learned as a Cancer Survivor - Pfizer
Tingting Zhang-Kharas Appointed Vice President, Search & Evaluation, Oncology at Pfizer - hrtoday.in
Pfizer building’s collapse scare tests whether New Yorkers will forget and rent anyway - Crain's New York
From Vaccines to Air Traffic: Poland’s Billion-Euro Dispute with Pfizer - finchannel
Pfizer stock trades steady as recent earnings and pipeline updates frame valuation - Ad-hoc-news.de
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Pfizer Suspends Popular Menopause Cream in India - Benzinga
Axios C-Suite: Pfizer CEO on biotech's China warning - Axios
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine - Yahoo Finance
Pfizer stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Unions seize on Pfizer conversion scare to push for contracts, reforms - The Real Deal
Pfizer site developer’s complex conversion technique draws attention after collapse scare - Crain's New York Business
Pfizer Inc. (PFE) Stock Analysis: Evaluating a 14.92% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? - The Globe and Mail
Lobbying Update: $60,000 of PFIZER lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged - TechStock²
Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention - IPWatchdog.com
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now - Yahoo Finance
Pfizer stock holds steady on 2025 profit and 2026 guidance - ad-hoc-news.de
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Encyclopedia Britannica
Pfizer Stock Near Lows But Analysts See Upside Ahead - TipRanks
The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant - Ad-hoc-news.de
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? - Yahoo Finance
How the Pfizer building scare could push developers to rethink vertical conversion plans - The Real Deal
1.18%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):